You are here

Comparative Effectiveness Study of Treatment of Sialorrhea in Patients with Amyotrophic Lateral Sclerosis

Difficultly swallowing can lead to problems managing saliva and excessive drooling (sialorrhea) in patients with amyotrophic lateral sclerosis (ALS). This symptom is both a social and medical burden to the patient and their family and drooling can lead to choking episodes which can cause aspiration pneumonia. While there are medications for managing saliva in ALS, the best medication with the most tolerable side effects is unknown. The aim of this initiative is to determine which of four standard of care medications is best in controlling drooling. Patients will be randomized to receive one of the following: 1) scopolamine patch (1.5 mg) transdermat every 72 hours; 2) glycopyrrolate 1 mg three times a day; 3) amitriptyline 25 mg at bedtime; and 4) atropine 1% sublingual drops 2 drops three times a day. The initiative will also determine the tolerability of each of the four treatments for drooling in patients using clinical and patient-generated information.


 

Other Information:

  • Principal Investigator: Richard Barohn, MD; University of Kansas Medical Center
  • Status: Application re-submitted in 2017

 


  Back to list of Initiatives